Yumanity Therapeutics, Inc. (NASDAQ:YMTX – Get Rating)’s stock price fell 0.4% during mid-day trading on Friday . The company traded as low as $2.50 and last traded at $2.60. 13,584 shares were traded during mid-day trading, a decline of 97% from the average session volume of 473,083 shares. The stock had previously closed at $2.61.
Yumanity Therapeutics Trading Down 0.4 %
The firm has a market cap of $28.23 million, a P/E ratio of -0.87 and a beta of 0.32. The stock has a 50 day simple moving average of $3.50 and a 200-day simple moving average of $4.60.
Hedge Funds Weigh In On Yumanity Therapeutics
Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its position in shares of Yumanity Therapeutics by 16.7% during the 2nd quarter. Renaissance Technologies LLC now owns 70,508 shares of the company’s stock valued at $128,000 after purchasing an additional 10,100 shares during the last quarter. Citadel Advisors LLC grew its position in Yumanity Therapeutics by 54.0% in the 3rd quarter. Citadel Advisors LLC now owns 49,543 shares of the company’s stock valued at $78,000 after acquiring an additional 17,364 shares during the last quarter. Jane Street Group LLC bought a new position in Yumanity Therapeutics in the 1st quarter valued at $35,000. Finally, Millennium Management LLC bought a new position in Yumanity Therapeutics in the 2nd quarter valued at $155,000. Institutional investors own 25.10% of the company’s stock.
Yumanity Therapeutics Company Profile
Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.
Featured Articles
- Get a free research report on Yumanity Therapeutics from StockNews.com
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Wayfair: From Steep Decline to Recent Surge
- Five stocks we like better than Yumanity Therapeutics
Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
